Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
Thursday, March 12, 2026
2 min read
Canonical SourceIndia
Summary Only
What Changed
Cipla launched its generic version of Saxenda® (Liraglutide Injection) in the US market, expanding its portfolio for weight management therapy.
Sigvera Intelligence
Source Trust:Discovery
Company ActivityView all
Source Report
Cipla has launched a generic version of Saxenda® (Liraglutide Injection) in the US for weight management therapy.
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
115 industry signalsProduct Launch
Source Verification
Verified from official source
Publisher—
Publication DateMar 12, 2026
Source ClassVerified Canonical
Signal Timeline
First ReportedMar 12, 2026
IndexedMar 12, 2026
PublishedMar 12, 2026
https://finance.yahoo.com/news/cipla-strengthens-us-portfolio-launch-162800584.html
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
Sign In